Core Insights - GRI Bio, Inc. is advancing a pipeline of Natural Killer T (NKT) cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases [1][3] - The company recently reported positive Phase 2a data in Idiopathic Pulmonary Fibrosis (IPF), highlighting significant biomarker improvements related to fibrosis and lung repair [2] Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on transforming the treatment landscape for inflammatory, fibrotic, and autoimmune diseases [3] - The company's therapies target NKT cells, which are crucial in regulating the inflammatory response and disease progression [3] - GRI Bio's lead program, GRI-0621, is an RARβγ agonist designed to inhibit iNKT cell activity and is being developed as an oral treatment for IPF, addressing a significant unmet medical need [3] - The company is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its growing pipeline [3]

Core Viewpoint - GRI Bio, Inc. has successfully closed a public offering of 10,666,667 shares of common stock and Series F warrants, raising approximately $8.0 million for product development and general corporate purposes [1][3]. Group 1: Offering Details - The public offering was priced at $0.75 per share, with Series F warrants exercisable at the same price [1]. - The Series F warrants are immediately exercisable and will expire five years from the issuance date [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [2]. Group 2: Financial Implications - The gross proceeds from the offering were approximately $8.0 million before deducting fees and expenses [3]. - If fully exercised, the Series F warrants could provide an additional $8.0 million in gross proceeds [3]. - The net proceeds will be allocated towards product candidate development, working capital, and general corporate purposes [3]. Group 3: Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on treating inflammatory, fibrotic, and autoimmune diseases through NKT cell modulation [6]. - The lead program, GRI-0621, targets iNKT cell activity for treating idiopathic pulmonary fibrosis, addressing a significant unmet medical need [6]. - The company is also developing a pipeline of NKT agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds [6].

Core Viewpoint - GRI Bio, Inc. has announced a public offering of 10,666,667 shares of common stock and Series F warrants, aiming to raise approximately $8 million for product development and general corporate purposes [1][3]. Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on treating inflammatory, fibrotic, and autoimmune diseases through Natural Killer T (NKT) cell modulators [6]. - The company's lead program, GRI-0621, is an inhibitor of iNKT cell activity, targeting idiopathic pulmonary fibrosis, a disease with significant unmet medical needs [6]. - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its pipeline [6]. Offering Details - The public offering is priced at $0.75 per share, with Series F warrants exercisable at the same price, expiring five years after issuance [1]. - The offering is expected to close around December 12, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. Financial Implications - The gross proceeds from the offering are anticipated to be approximately $8 million before deducting fees and expenses [3]. - If fully exercised, the Series F warrants could provide an additional $8 million in gross proceeds [3].

Core Insights - GRI Bio, Inc. reported no decline in lung function in patients treated with GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) during a 6-week interim analysis, indicating potential efficacy and safety of the treatment [1][2][3] - The Phase 2a study is fully enrolled, with topline data expected in Q3 2025, highlighting the company's commitment to advancing its innovative pipeline [1][5] Company Overview - GRI Bio is a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases [6] - The lead program, GRI-0621, is an oral therapeutic aimed at treating IPF, a disease with significant unmet medical needs [6] Study Details - The Phase 2a study is a randomized, double-blind, placebo-controlled trial involving approximately 35 subjects with IPF, comparing GRI-0621 (4.5mg) to a placebo over 12 weeks [3][4] - The primary endpoint is the safety and tolerability of GRI-0621, while secondary endpoints include changes in serum biomarkers and pharmacokinetics [3][4] Interim Analysis Findings - The interim analysis showed no worsening of forced vital capacity (FVC) in GRI-0621 treated patients, along with positive changes in biomarkers suggesting an anti-fibrotic effect [2][3] - Independent Data Monitoring Committee (IDMC) found GRI-0621 to be safe and well-tolerated, recommending the continuation of the study [4][2] Future Expectations - Topline results from the Phase 2a biomarker study are anticipated in Q3 2025, with additional data on flow cytometry and gene expression expected in the coming months [5]

Company Overview - GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on treating inflammatory, fibrotic, and autoimmune diseases through innovative therapies targeting Natural Killer T (NKT) cells [3] - The company's lead program, GRI-0621, is an oral therapeutic aimed at inhibiting iNKT cell activity for the treatment of idiopathic pulmonary fibrosis, addressing a significant unmet medical need [3] - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its growing pipeline [3] Upcoming Events - Marc Hertz, PhD, CEO of GRI Bio, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 3:00 PM ET in New York, NY [1] - Management will be available for in-person one-on-one meetings with qualified investors registered for the conference [2] - A live webcast of the presentation will be available on the company's website, with a replay archived for 90 days post-event [2]

Company Overview - GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on treating inflammatory, fibrotic, and autoimmune diseases through innovative therapies targeting Natural Killer T (NKT) cells [3] - The company's lead program, GRI-0621, is an oral therapeutic aimed at inhibiting iNKT cell activity for the treatment of idiopathic pulmonary fibrosis, addressing a significant unmet medical need [3] - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus, supported by a library of over 500 proprietary compounds [3] Upcoming Presentation - GRI Bio will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech from August 19-21, 2025, with a specific presentation scheduled for August 20, 2025, at 2:20 PM ET [1] - The presentation will be led by Marc Hertz, PhD, who serves as the President, Chief Executive Officer, and Director of GRI Bio [1]

Company Overview - GRI Bio, Inc. is a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases [3] - The company is in the clinical stage and aims to fundamentally change treatment approaches for these diseases [3] Recent Developments - GRI Bio participated in a Virtual Investor segment where CEO Marc Hertz discussed interim biomarker data from a Phase 2a study in Idiopathic Pulmonary Fibrosis (IPF) [2] - The interim data was collected over a 6-week period, indicating progress in the ongoing study [2] Product Pipeline - GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity, being developed as an oral therapeutic for IPF, which has significant unmet medical needs [3] - The company is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists aimed at treating systemic lupus erythematosus [3] - GRI Bio possesses a library of over 500 proprietary compounds, which supports the expansion of its product pipeline [3]

Core Insights - GRI Bio, Inc. is advancing its Phase 2a study of GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), showing promising interim biomarker results that indicate a positive impact on fibrogenesis and fibrolysis [1][2][3] - The Independent Data Monitoring Committee (IDMC) has recommended the continuation of the study as there are no safety concerns observed in the interim data [1][4][6] - Topline data from the Phase 2a study is expected in Q3 2025, with additional pulmonary function test data anticipated in the coming weeks [7] Company Overview - GRI Bio is a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases [1][8] - The lead program, GRI-0621, is designed to inhibit iNKT cell activity and is being developed as an oral therapeutic for IPF, addressing a significant unmet medical need [8] Study Details - The Phase 2a study is a randomized, double-blind, multi-center, placebo-controlled trial involving approximately 35 subjects with IPF, randomized in a 2:1 ratio for GRI-0621 (4.5mg) or placebo [3][4] - The primary endpoint is the safety and tolerability of GRI-0621, while secondary endpoints include changes in serum biomarkers and pharmacokinetics [3][4] Interim Results - The 6-week interim analysis showed a favorable reduction in fibrogenesis biomarkers and an improved fibrolytic profile in GRI-0621 treated patients compared to the control group [2][3] - The results indicate increased basement membrane remodeling and potential initiation of a repair response in patients treated with GRI-0621 [2][3] Future Expectations - The company anticipates reporting topline data later this year, along with findings regarding pulmonary function and additional biomarker data [3][7]

Core Insights - GRI Bio, Inc. is a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases [1][3] - The company’s lead program, GRI-0621, is an oral therapeutic aimed at treating idiopathic pulmonary fibrosis, addressing a significant unmet medical need [3] - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus, supported by a library of over 500 proprietary compounds [3] Company Overview - GRI Bio is a clinical-stage biopharmaceutical company aiming to change the treatment landscape for inflammatory, fibrotic, and autoimmune diseases [3] - The company’s therapies target NKT cells, which play a crucial role in the inflammatory response and disease progression [3] - The company’s focus on NKT cells positions it uniquely in the biopharmaceutical industry, linking innate and adaptive immune responses [3] Leadership Insights - Dr. Marc Hertz, the President and CEO, shared his dedication to the company and insights into its development programs during a recent investor conference [2]

Core Insights - GRI Bio, Inc. has completed patient enrollment for its Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) [1][2] - The company is on track to report 6-week interim biomarker results in July 2025, with topline data expected in Q3 2025 [1][6] - GRI-0621 is being developed as a novel oral therapeutic targeting Natural Killer T (NKT) cells, which play a critical role in inflammatory and fibrotic diseases [8] Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on treating inflammatory, fibrotic, and autoimmune diseases through NKT cell modulation [8] - The lead program, GRI-0621, is an inhibitor of iNKT cell activity aimed at addressing the unmet needs in IPF treatment [8] Study Design and Results - The Phase 2a study is a randomized, double-blind, placebo-controlled trial enrolling approximately 35 subjects, with a 2:1 randomization for GRI-0621 (4.5mg) versus placebo [3] - Primary endpoint focuses on safety and tolerability after 12 weeks, while secondary endpoints include changes in serum biomarkers and pharmacokinetics [3] - Interim safety results from the first 12 and 24 patients indicated that GRI-0621 is safe and well-tolerated, with no significant changes in lipid levels observed [4][5] Future Expectations - The company anticipates reporting 6-week interim biomarker data in July 2025, followed by topline results in Q3 2025 [6]